Behçet's Disease: Recurrent Mouth Ulcers

Behçet's Disease Overview and Epidemiology

Behçet's disease represents a chronic, multi-system vasculitis of unknown etiology characterized by recurrent oral ulcers, genital ulcers, ocular involvement (uveitis), and mucocutaneous lesions. First described by Turkish dermatologist Hulusi Behçet in 1937, the disease occurs along a geographic "Silk Road" distribution pattern, with highest prevalence in Turkey (80-370 cases per 100,000), parts of the Middle East, North Africa, and East Asia (Japan 13-20 per 100,000). Prevalence in North America and northern Europe remains lower (0.1-0.6 per 100,000), likely reflecting both genetic predisposition and potential environmental triggers.

The disease typically begins in the second to fourth decade of life, though childhood onset occurs in 10-15% of cases. Men experience more severe disease than women overall, though women experience more frequent genital ulceration. The oral ulcers, present in 95-99% of patients, represent often the initial manifestation and most frequent symptom throughout disease course. Dentists frequently encounter Behçet's patients presenting with recurrent aphthous ulcers, making familiarity with diagnostic criteria and management essential.

Diagnostic Criteria: International Study Group Classification

The International Study Group established standardized diagnostic criteria for Behçet's disease in 1990, requiring recurrent oral ulcers (mandatory criterion) plus two of the following: 1) recurrent genital ulcers; 2) ocular lesions (uveitis, hypopyon); 3) skin lesions (papulopustules, nodules, erythema nodosum); or 4) positive pathergy test (abnormal hypersensitivity reaction to minor trauma).

Recurrent oral ulcers in Behçet's disease are characterized by: 1) Frequency: three or more episodes within 12 months; 2) Morphology: 1-3cm diameter ulcers with erythematous halo and yellowish-white pseudomembrane; 3) Duration: healing within 1-3 weeks without scarring in most cases (though larger ulcers may scar); 4) Distribution: typically anterior oral cavity (buccal mucosa, attached gingiva, palate, dorsum of tongue).

The pathergy test—puncturing the skin with a sterile needle and observing for papule formation at 48 hours—is positive in 70-80% of Turkish and Mediterranean patients with Behçet's disease but positive in only 10-15% of Japanese patients, reflecting ethnographic variation. While sensitive in Mediterranean populations, pathergy test is seldom necessary for diagnosis in regions where oral ulcers, genital ulcers, and ocular findings are present.

Pathogenesis and Immunologic Mechanisms

Behçet's disease pathogenesis involves both innate and adaptive immune dysregulation. The disease shows strong association with HLA-B51 (present in 60-90% of Behçet's patients vs. 3-10% of controls), particularly in Mediterranean and Middle Eastern populations. However, HLA-B51 is neither sufficient nor necessary for disease development—suggesting additional genetic and environmental factors.

The disease demonstrates neutrophil hyperactivation, with elevated neutrophil function, increased spontaneous activation, and exaggerated response to inflammatory stimuli. This hyperactivation drives oral ulceration—neutrophils infiltrating oral epithelium create the characteristic ulcer morphology. Elevated serum IL-6, IL-8, and TNF-alpha levels reflect systemic inflammation that correlates with disease severity.

Endothelial cell activation and T-cell mediated vasculitis characterize tissue pathology. Histology reveals leukocytoclastic vasculitis with fibrinoid necrosis of small and medium-sized vessels. Molecular mimicry between streptococcal antigens and Behçet's autoantigens has been proposed as a potential trigger, though not universally accepted.

Clinical Characteristics of Oral Ulcers

Oral ulcers in Behçet's disease display consistent characteristics: they begin with localized erythema and edema, rapidly progressing to painful ulceration with yellowish-white pseudomembrane. The ulcers range from 2-10mm (minor form, most common) to >10mm (major form, less common), with the major form healing over 2-3 weeks while minor ulcers resolve in 1-2 weeks. Some ulcers scar, particularly the larger major form.

The ulcers recur with variable periodicity—some patients experience continuous ulceration (new ulcers forming before previous ulcers heal), while others experience months between recurrences. Frequency often increases during stress, illness, or seasonal changes (worse in winter in some populations).

Oral ulcers cause significant pain that may interfere with eating and speaking. Unlike minor aphthous ulcers in non-Behçet's patients, Behçet's oral ulcers are often larger (>1cm), more frequent (three within 12 months), and more numerous (multiple simultaneous ulcers common).

Systemic Manifestations and Ocular Involvement

Genital ulcers, present in 70-80% of Behçet's patients, develop during or after oral ulcers in most cases. They appear on the scrotum, penis (men) or vulva, vagina (women), are typically larger and more painful than oral ulcers, and heal with scarring in up to 50% of cases. Genital scarring can cause sexual dysfunction and fertility complications.

Ocular involvement occurs in 50-70% of patients, typically posterior uveitis (affecting retina and choroid) rather than anterior uveitis. Hypopyon (leukocyte accumulation in anterior chamber) represents a pathognomonic finding. Severe ocular disease causes vision loss through retinal vasculitis, optic neuritis, or glaucoma. Ocular involvement carries the worst prognosis, potentially leading to blindness without appropriate immunosuppression.

Skin manifestations include recurrent folliculitis, papulopustules, nodules, and erythema nodosum. Neurologic involvement (neuro-Behçet's) occurs in 5-10% of patients, presenting with brainstem syndrome, meningoencephalitis, cognitive decline, or myelitis.

Dental Management and Pharmacologic Treatment

Oral ulcer management in Behçet's patients begins with topical treatment: triamcinolone acetonide 0.1% applied directly to ulcers in Orabase formulation four times daily (after meals and before bedtime) significantly accelerates healing and reduces pain. Topical anesthetics (benzocaine) provide symptomatic relief but do not affect healing. Antimicrobial mouthwashes (chlorhexidine 0.12%) reduce secondary bacterial infection risk but are not primary treatment.

Systemic management depends on disease severity: Colchicine (0.5-1.5mg daily divided in 2-3 doses) represents the first-line pharmacologic treatment, reducing oral ulcer frequency and severity by 50% in controlled trials, and preventing genital ulceration and erythema nodosum. Colchicine's mechanism involves inhibition of neutrophil migration and inflammatory mediator release.

Topical and systemic corticosteroids (prednisolone 0.5-1mg/kg initially, tapering as tolerated) suppress inflammation more rapidly than colchicine alone and are indicated for severe disease. However, corticosteroids carry long-term complications (osteoporosis, metabolic effects) necessitating steroid-sparing alternative strategies.

Immunosuppressive agents—azathioprine, mycophenolate, or methotrexate—serve as steroid-sparing agents for moderate-to-severe disease or steroid-dependent patients. TNF-alpha inhibitors (infliximab, adalimumab, etanercept) demonstrate efficacy in severe or refractory disease, with dramatic improvement in oral ulcers, genital ulcers, and particularly eye disease when conventional treatments fail.

Dental Hygiene Modifications and Lifestyle

Patients with active oral ulcers require modified oral hygiene techniques to minimize trauma: gentle brushing with ultrasoft toothbrushes, use of electric toothbrushes (paradoxically less traumatic than manual brushing due to minimal pressure requirement), salt-water rinses, and avoidance of spicy or acidic foods that exacerbate ulcer pain.

Trauma avoidance represents a critical management principle—foods with sharp edges (chips, nuts, crusty bread), dental procedures causing mucosal injury (aggressive scaling, sharp restorations), or ill-fitting dentures perpetuate ulceration through the pathergy phenomenon. Dental professionals should minimize mucosal trauma during routine care and defer elective procedures until ulcer remission, if feasible.

Stress management, adequate sleep, and seasonal awareness (some patients experience winter exacerbations) support clinical improvement. Patients who recognize seasonal patterns may benefit from prophylactic colchicine dosage increase during high-risk seasons.

Differential Diagnosis

Behçet's disease must be distinguished from other causes of recurrent oral ulcers: Minor aphthous ulcers (smaller, less frequent, no systemic findings); recurrent herpetic stomatitis (clustered vesicles, prodromal symptoms); aphthous ulcers secondary to celiac disease, inflammatory bowel disease, or immunodeficiency; and drug-induced ulcers. The combination of oral and genital ulcers with ocular involvement—present in Behçet's disease but not these alternatives—usually clarifies diagnosis.

Histology, while not required for diagnosis, shows dense lymphocytic infiltration around oral ulcers and ulcerative vasculitis. Culture excludes infectious causes.

Patient Information and Support

Patients newly diagnosed with Behçet's disease benefit from understanding that disease severity varies significantly, that oral ulcers, while symptomatic, do not cause permanent oral damage (except in major form with scarring), and that effective treatments exist to control symptoms and prevent serious complications (particularly ocular). Referral to rheumatology is essential for systemic disease management, though dentists play important roles in oral disease recognition and topical management.

Conclusion

Behçet's disease represents a significant cause of recurrent oral ulcers, particularly in patients of Mediterranean, Middle Eastern, or East Asian descent. Dentists encountering patients with recurrent oral ulcers (three within 12 months) should screen for systemic manifestations, particularly genital ulcers and ocular symptoms. Recognition of diagnostic criteria enables appropriate medical referral and systemic workup. Dental management focuses on local treatment (topical corticosteroids) and trauma avoidance, with systemic treatment—colchicine, immunosuppressants, and biologic agents—coordinated through rheumatology. Understanding this condition enables dentists to provide appropriate supportive care and prevent delayed diagnosis of this important systemic disease.